Table 1.

Baseline characteristics of 481 participants in the NEFRONA cohort study according to plasma fibroblast growth factor 2 (FGF-2) concentration

CharacteristicAll (n=481)Lower Tertile, 3–64 pg/ml (n=160)Middle Tertile, 65–119 pg/ml (n=160)Higher Tertile, 120–865 pg/ml (n=161)
Age, yr61 (52–68)61 (53–68)61 (50–68)61 (50–68)
Men, N (%)295 (61)107 (67)94 (59)94 (58)
History of smoking, N (%)283 (59)91 (61)88 (55)98 (61)
Dyslipidemia, N (%)336 (70)107 (67)114 (71)115 (71)
Diabetes mellitus, N (%)137 (29)43 (27)51 (32)43 (27)
Hypertension, N (%)442 (92)150 (94)147 (92)145 (90)
Systolic BP, mm Hg142 (20)142 (20)142 (20)141 (20)
Diastolic BP, mm Hg81 (10)81 (11)81 (10)81 (11)
Total cholesterol, mg/dl180 (156–207)179 (148–206)184 (165–209)180 (157–206)
LDL cholesterol, mg/dl104 (85–126)102 (75–124)106 (93–128)104 (87–128)
HDL cholesterol, mg/dl47 (38–59)47 (39–58)47 (37–61)47 (39–61)
Triglycerides, mg/dl127 (90–171)133 (89–171)133 (91–180)117 (88–164)
Glucose, mg/dl98 (88–114)99 (87–111)99 (90–129)95 (89–112)
25-hydroxyvitamin D, ng/ml16.7 (11.9–21.4)16.1 (12.0–21.0)17.5 (12.2–21.9)15.7 (11.1–21.2)
Intima-Media Thickness, mm0.86 (0.67–1.1)0.86 (0.71–1.14)0.86 (0.65–1.1)0.84 (0.64–1.1)
HsCRP, mg/L2.12 (1.13–4.52)2.12 (1.04–4.52)1.97 (1.15–4.36)2.16 (1.21–4.73)
CKD stage, N (%)
 3243 (51)58 (36)89 (56)96 (60)
 4–5199 (41)71 (44)67 (42)61 (38)
 Dialysis39 (8)31 (20)4 (2)4 (2)
Plaque present at baseline, N (%)335 (70)115 (72)106 (66)114 (71)
FGF-2, pg/ml85 (55–138)43 (26–55)85 (73–100)164 (138–204)
  • Dyslipidemia: diagnosis of dyslipidemia in the clinical history. Data are median (25th to 75th percentile) for quantitative variables non-normally distributed, mean (SD) for normal variables, and number (percentage) for categorical variables. HsCRP, high-sensitivity C-reactive protein.